#	Aladdin ID	Assay Type	Description	Organism	Compounds	Reference	BAO Format	Source
1.	ALA1024879	F	Inhibition of Vaccinia virus DNA synthesis in by rapid plate assay	Vaccinia virus	93	ALA1140145	organism-based format	Scientific Literature
2.	ALA1024886	F	Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as reduction in plaque formation up to 200 uM after 20 hrs	Vaccinia virus	19	ALA1140145	organism-based format	Scientific Literature
3.	ALA1024887	F	Antiviral activity against Vaccinia virus WR in BSC1 cells assessed as protection from virus-induced lysis of cell monolayer up to 200 uM after 20 hrs	Vaccinia virus	19	ALA1140145	organism-based format	Scientific Literature
4.	ALA1024888	A	Cytotoxicity against african green monkey BSC1 cells up to 200 uM after 20 to 120 hrs WST-1 based assay	Chlorocebus aethiops	19	ALA1140145	cell-based format	Scientific Literature
5.	ALA1040691	F	NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay	Plasmodium falciparum	5,614	ALA1156829	organism-based format	Novartis Malaria Screening
6.	ALA1040692	F	NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay	Plasmodium falciparum	5,614	ALA1156829	organism-based format	Novartis Malaria Screening
7.	ALA1040693	T	NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)	Homo sapiens	5,614	ALA1156829	cell-based format	Novartis Malaria Screening
8.	ALA1040694	F	NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.		5,614	ALA1156829	assay format	Novartis Malaria Screening
9.	ALA1789905	F	NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence.	Plasmodium yoelii	4,416	ALA1789904	organism-based format	Novartis Malaria Screening
10.	ALA2028070	F	MMV: Inhibition of Plasmodium falciparum 3D7 at 5uM compound concentration.	Plasmodium falciparum	315	ALA2028040	organism-based format	MMV Malaria Box
11.	ALA2028071	F	MMV: Inhibition of Plasmodium falciparum 3D7 (EC50).	Plasmodium falciparum	317	ALA2028040	organism-based format	MMV Malaria Box
12.	ALA2028072	F	MMV: Inhibition of Plasmodium falciparum K1 (EC50).	Plasmodium falciparum	171	ALA2028040	organism-based format	MMV Malaria Box
13.	ALA2028073	F	MMV: Inhibition of Trypanosoma cruzi (Tulahuen C4 LacZ) (Chagas in vitro).	Trypanosoma cruzi	400	ALA2028040	organism-based format	MMV Malaria Box
14.	ALA2028074	F	MMV: Inhibition of Trypanosoma brucei brucei (Squib 427) (HAT in vitro).	Trypanosoma brucei brucei	400	ALA2028040	organism-based format	MMV Malaria Box
15.	ALA2028075	F	MMV: Inhibition of Trypanosoma brucei rhodesiense (STIB 900) (HAT in vitro).	Trypanosoma brucei rhodesiense	400	ALA2028040	organism-based format	MMV Malaria Box
16.	ALA2028076	F	MMV: Inhibition of Leishmania infantum (MHOM/MA/BE/67) in vitro.	Leishmania infantum	400	ALA2028040	organism-based format	MMV Malaria Box
17.	ALA2028077	T	MMV: Cytotoxicity against human fibroblasts (MRC-5) cells.	Homo sapiens	400	ALA2028040	cell-based format	MMV Malaria Box
18.	ALA2094261	F	MMV: Screen against Mtb, single point, non replicating, at 25uM	Mycobacterium tuberculosis	399	ALA2094260	organism-based format	MMV Malaria Box
19.	ALA2094262	F	MMV: Screen against Mtb, single point, replicating, at 25uM	Mycobacterium tuberculosis	399	ALA2094260	organism-based format	MMV Malaria Box
20.	ALA2094263	F	MMV: CRC and MIC90 against Mtb (non replicating)	Mycobacterium tuberculosis	55	ALA2094260	organism-based format	MMV Malaria Box